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Abstract.
Background: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-
(A) peptide between cerebrospinal fluid (CSF) and plasma compartments.
Objective: To determine whether plasma exchange (PE) with albumin replacement was able to modify A concentrations
in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer’s disease (AD).
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Methods: In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients
were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5%
albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and
one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF A1–40 and A1–42 levels, as well as
cognitive, functional, and behavioral measures were determined.
Results: CSF A1–42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls
(adjusted means of variation: 75.3 versus –45.5 pg/mL; 95% CI: –19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma A1–42
levels were lower in the PE-treated group after each treatment period (p < 0.05). Plasma A1–40 levels showed a saw-tooth
pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency
(p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase (p < 0.05).
Conclusion: PE with human albumin modified CSF and plasma A1–42 levels. Patients treated with PE showed improvement
in memory and language functions, which persisted after PE was discontinued.
Keywords: Albumin, Alzheimer’s disease, CSF A, plasma A, plasma exchange
INTRODUCTION
Alzheimer’s disease (AD) is the most frequent
form of dementia in the adult, and its prevalence
increases exponentially with age [1]. AD is a neu-
rodegenerative process characterized by progressive
cognitive deficits in multiple cognitive domains and
impairments in activities of daily living, as well
as neurological and psychiatric symptoms [2]. The
initial pathological event that leads to neurodegen-
eration (neuronal and synaptic loss) is unknown.
However, the accumulation of extracellular amyloid-
 (A) in the form of diffuse and neuritic plaques
and intracellular accumulation of phosphorylated
tau in the form of neurofibrillary tangles, neuropil
threads, and dystrophic neurites constitutes the most
salient neuropathological feature [3]. Only symp-
tomatic therapies are available for the treatment of
AD, and disease-modifying compounds are currently
being tested, especially medications that target A
metabolism [4, 5].
Aggregation and accumulation of A proteins in
the brain has been considered a defining pathology
associated with AD [3], and it has been suggested
that the sporadic form of AD is related to decreased
clearance of A from the central nervous system
(CNS) [6]. A proteins are the most important com-
ponent of the neuritic (senile) plaque (SNP). A1–42
is the predominant form in the SNP, and is deposited
first, while the A1–40 is deposited later [7]. CSF
A1–42 levels are decreased in AD patients, while
A1–40 levels remain normal [8]. Similarly, A pro-
teins are detectable in plasma; some studies have
shown increased A1–42 levels in early AD [9],
while others have shown decreased A1–42 levels,
and A1–42/A1–40 ratio [10].
Studies conducted in animal models and humans
have detected the presence of a bidirectional flow
of A peptide between the CSF and plasma com-
partments [11–13]. It has been reported that direct
transport of A through the blood-brain barrier repre-
sents 25% of its clearance [14] in cognitively normal
humans. Studies conducted in animal models showed
that the elimination half-life of A between CSF and
plasma is about 30 minutes [12, 15, 16]. Plasma lev-
els of A decrease as the deposits of the latter within
the brain increase [17]. These findings suggest that
there is equilibrium between plasma and CNS A,
and that SNP are continuously creating a new equi-
librium because A not only enters the plasma but
also deposits in the CNS [18]. This dynamic equilib-
rium between A in plasma and brain can be altered
with therapeutic interventions that target A pathol-
ogy. Peripheral sequestration of plasma A resulted
in a reduction of A in both the CSF and in the brain
of transgenic mice [19].
PE is a process used to remove patient plasma and
replace it with another solution, maintaining normal
volemia and osmotic balance, with the purpose of
eliminating toxic substances from plasma such as
autoantibodies, alloantibodies, immune complexes,
proteins, and toxins [20]. To this effect, albumin is
frequently used as the replacement solution in PE.
By taking advantage of the fact that the vast major-
ity of A circulating in blood (around 90%) is bound
to albumin in a 1:1 ratio [21], preliminary phase I
studies in humans using plasma exchange (PE) with
5% human albumin (Albutein®) showed that PE was
able to induce alterations in the A1–42 mobilization
(i.e., a trend to increase in CSF and a clear decrease
in plasma after the PE period, returning to baseline
levels at 6 months of follow-up) and that this finding
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may be related to a tendency of stabilizing the scores
in cognition tests, even after 1 year of follow-up [22].
In a confirmation of the occurrence of A mobiliza-
tion in CSF and plasma which was associated with
improved scores in cognitive tests, in this study, we
further describe and test PE with albumin replace-
ment as a novel strategy for the treatment of AD.
MATERIALS AND METHODS
This was a multicenter, randomized, patient- and
rater-blind, controlled phase II trial (EudraCT num-
ber: 2007-000414-36), conducted in compliance with
a clinical protocol, regulatory requirements, good
clinical practice (GCP), and the ethical principles of
the latest revision of the Declaration of Helsinki as
adopted by the World Medical Association. The study
was reviewed and approved by Independent Ethics
Committees (IEC) and Institutional Review Boards
(IRB).
Objectives
The primary objective was to determine whether
PE treatment with 5% human albumin was able to
modify the concentration of A (A1–40 and A1–42)
in CSF in patients with mild to moderate AD.
The secondary objectives were: 1) to determine
whether the treatment was able to modify the con-
centrations of A in plasma; 2) to assess the effects
of PE on cognitive, functional, and behavioral out-
comes; and 3) to evaluate the safety of the treatment
by monitoring adverse reactions and clinically rele-
vant changes during and after the PE procedure.
Patients
Patients were recruited from four different sites,
two in Spain (Fundacio´ ACE – Institut Catala´ de Neu-
rocie`ncies Aplicades in Barcelona, where patients
from the Hospital General Universitari Vall d’Hebron
in Barcelona were also included, and the Hospital
General Universitario Gregorio Maran˜o´n in Madrid)
and two in the USA (Alzheimer’s Research Cor-
poration – Mid Atlantic Geriatric Association in
Manchester, NJ, and Howard University in Washing-
ton, DC). The inclusion criteria were: 1) age 55–85;
2) meet the NINCDS-ADRDA criteria for probable
AD [23]; 3) Mini-Mental State Examination (MMSE)
[24] scores between ≥18 and ≤26); 4) be in a stable
dose of a cholinesterase inhibitors for the previ-
ous three months; and 5) absence of cerebrovascular
disease by clinical history and by computed axial
tomography (CAT) or magnetic resonance imaging
(MRI).
The exclusion criteria were: 1) Any contraindi-
cation or difficulty for PE (e.g., difficult venous
access, behavioral disorders, a history of frequent
adverse reactions to blood products; hypersensitiv-
ity to albumin or allergies to any of the components
of human albumin 5%); 2) abnormal coagulation
or laboratory parameters (e.g., hypocalcemia Ca++
<8.7 mg/dL; thrombocytopenia <100,000/L; fib-
rinogen <1.5 g/L; prothrombin time [Quick] p < 60%
versus control); 3) angiotensin-converting enzyme
inhibitors or beta-blocker treatment; 4) brady-
cardia <60/min; 5) plasma creatinine >2 mg/dL;
alanine aminotransferase >2.5 × upper limit of nor-
mal; bilirubin >2 mg/dL; 6) uncontrolled high blood
pressure; 7) heart disease; 8) participation in other
clinical trials or the use of any other investigational
drug in the three months prior to the start of the study;
9) fewer than six years of education; and 10) any
condition that complicated adherence to the study
protocol.
The patient and a close relative or legal representa-
tive signed the informed consent form to participate
in the trial.
Study design
The time between screening and randomization
(1:1 ratio to either the control group or the PE-treated
group) was two weeks. The PE treatment consisted of
processing approximately one whole plasma volume
with simultaneous substitution by the same volume of
5% human albumin, a procedure specifically known
as Total Plasma Exchange. The PE treatment was
provided in three periods of six PE each: 1) Inten-
sive treatment period: three weeks with two PE per
week; 2) Maintenance treatment period I: six weeks
with one PE per week; and 3) Maintenance treatment
period II: 12 weeks with one PE every two weeks. The
control group underwent a sham treatment (simulated
PE without invasive procedures).
The patients were followed during the treatment
phase of the study (first 21 weeks), and during an
additional six-month period, where they had two vis-
its every three months (weeks 33 and 44 ± 7 days).
Patients’ physical and clinical data were collected
throughout the study (baseline and visits at weeks
3, 9, 21, 33, and 44). All evaluators of laboratory
and psychometric testing were blinded to patient
treatment.
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Randomization and masking
Eligible patients were randomly assigned (1:1) to
PE treatment or control (simulated plasma exchange
without invasive procedures: sham) groups using
a SAS computer-generated sequence that was pro-
grammed by an independent, unmasked, statistical
team at a contract research organization (Trial Form
Support – TFS). The randomization codes were kept
in envelopes that were opened each time a patient
was randomized. In sham treatment, gauze dressing
was placed on the subclavicular region, affixing a dual
lumen catheter of characteristics similar to the central
catheters used in the treatment group, and proce-
dures mimicking PE were carried out [22]. Likewise,
these patients undertook the same visits schedule
and assessments as the patients in the treatment
group.
All evaluators of laboratory and psychometric test-
ing were blinded to patient treatment. Importantly,
the evaluators of the neuropsychological tests did not
have access to any kind of information allowing them
to identify the patient’s assignment to treatment. The
patient care takers or informers were instructed not
to mention any details about the treatment during the
neuropsychological tests.
Product and study procedures
The human albumin product for PE was
Human Albumin Grifols®/Albutein® 5% (Grifols,
Barcelona, Spain). Approximately one plasma vol-
ume was processed in each PE, calculated from
body weight, height, and hematocrit (approxi-
mately 35–45 mL/kg, corresponding to a volume
of 2500–3000 mL for a 70 kg. subject). The
same volume of Albutein® 5% was administered
(60–100 ml/min) as a replacement fluid to the treat-
ment group (50 g of albumin per liter of replaced
plasma). This is considered a standard PE procedure
and is the same that was used in the preliminary phase
I studies [22].
For each treatment period (intensive, maintenance
I, maintenance II), a baseline lumbar puncture (before
the start of treatment) and a lumbar puncture imme-
diately after the end of the last PE were performed
to collect CSF samples. Lumbar punctures were also
performed during the follow-up period (weeks 33 and
44). Plasma samples were collected before and at the
end of each PE. A levels were determined from the
samples. Before every PE, a physical examination
was carried out.
Lumbar puncture and blood sampling were car-
ried out following the standard techniques of each
center. CSF collection (discarding the first few mL
of fluid) was as follows: 3 mL for general testing
(kept at room temperature, with immediate analy-
sis); and 3 mL for A determination (collected in
polypropylene tubes, which could be immediately
frozen at –80◦C until analysis). For blood collec-
tion (with EDTA), recommendations were as follows:
5 mL for coagulation parameters and hematolog-
ical tests; 10 mL for proteinogram, biochemistry,
and serology; 4 mL (approximately 2 mL of plasma)
for ApoE determination; and 10 mL (approximately
5 mL of plasma) in polypropylene tubes for A
determination.
Efﬁcacy variables
Efficacy outcomes included the variation of
A1–40 and A1–42 levels in CSF during the treat-
ment period, between baseline and at the end of the
last PE, as well as the variation between the beginning
and finalization of each of the three treatment periods.
Based on the observations of the preliminary phase
I studies [22], the difference of CSF A1–42 levels
between the treatment group and the control group at
the end of the last PE considered to be feasible was
100 pg/ml.
CSF and plasma levels of A1–40 were deter-
mined with the h Amyloid A1–40 ELISA (The
Genetics Company; TGC). CSF and plasma levels
of A1–42 were determined with the high-sensitivity
Innotest -amyloid(1–42) (Innogenetics, now Fujire-
bio Diagnostic Inc.) with a determination cutoff limit
of 7.8 pg/mL.
Clinical efficacy measures included global cog-
nitive measures such as the MMSE [24], and the
Alzheimer’s Disease Assessment Scale, cognitive
subscale (ADAS-Cog) [25], and selected lan-
guage/attention neuropsychological tests: 1) Symbol
Digit Modalities Test (SDMT) [26], 2) Semantic Ver-
bal Fluency (SVF) [27], 3) Phonemic Verbal Fluency
(PVF) [27], 4) Boston Naming Test (BNT) [28], and
5) Rey Auditory Verbal Learning Test (RAVLT) [29].
Behavioral measures included: 1) the Neuropsychi-
atric Inventory (NPI) [30], 2) the Cornell Scale for
Depression in Dementia (CSDD) [31], 3) the Overt
Aggression Scale (OAS) [32], and 4) the Agitated
Behavior Scale (ABS) [33]. Functional measures
included: 1) the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living (ADCS-ADL) [34],
2) the Alzheimer’s Disease Cooperative Study –
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Clinical Dementia Rating – Sum of boxes (CDR-sb)
[35], and 3) the Clinical Global Impression of Change
(ADCS-CGIC) [36].
Safety assessments
The primary assessment of safety was the num-
ber and percentage of patients with at least one
adverse effect (AE) that could be related or not to
the study procedure. The AE were coded according
to the classification of the World Health Organi-
zation (WHO) (MedDRA version 13.1), and were
described by a synonym (Lowest Level Term) and
the affected organ/system, the intensity, causality and
seriousness.
Statistical analysis
A sample size of 36 patients (18 per group) was
calculated for the study to have 80% power for the
primary efficacy variable (variation in A1–42 levels
in CSF from the baseline visit to the last available
measurement), a difference of 220 pg A1–42/mL
between means of the treatment and control groups,
assuming the common standard deviation (SD) to be
217.4 pg/mL (according to data obtained in the pre-
liminary phase 1 studies) [22], using the Student t-test
with a two-sided level of significance of 5%. Assum-
ing a global dropout rate of approximately 15%, the
study had to enroll 42 patients to obtain 36 patients
for evaluation.
All patients with at least three PE sessions dur-
ing the intensive treatment period were considered
for efficacy analysis (intention-to-treat [ITT] popu-
lation). A second analysis was also conducted on
the per-protocol (PP) population, which included
the patients who completed the treatment with-
out breaches in the study protocol, determined
before the randomization was unblinded. All the
patients included in the study and subjected to at
least one PE session were included in the safety
population.
The analysis of the variation in A1–40 and A1–42
levels was carried out by an analysis of covariance
(ANCOVA) with adjusted (least-squares) mean and
95% confidence intervals (CI) as output and the
change from baseline in A in CSF at the last avail-
able measurement as dependent variable, treatment
group as a factor, and the baseline level of A as a
covariate. The following variables were descriptively
analyzed by treatment group: variation in A1–40
and A1–42 levels in CSF between the end and start
of each of the three treatment periods; variation in
A1–40 and A1–42 levels in CSF between the treat-
ment phase and follow up; and variation of A1–40
and A1–42 levels in plasma before and after each PE
and follow up.
The clinical measures were examined with a mixed
model for repeated measures between-group differ-
ences in test scores at end of PE treatment (week
21) and end of follow up (week 44). The depen-
dent variable in each analysis was the change from
baseline in test score. Fixed effects were treatment
(PE-treated or control group), visit, and treatment-
by-visit interaction. No adjustments for multiple
comparisons or corrections for multiplicity were
planned.
Data are presented as median and range or as
mean ± standard deviation (SD) or ± 95% CI, when-
ever appropriate. Statistical significance was set at 5%
level. The SAS® software (SAS Institute Inc., Cary,
NC, USA) version 9.2 was used for calculations.
RESULTS
Patients characteristics
A total of 48 patients that met the inclusion crite-
ria were enrolled and signed the informed consent,
with no screening failures. Forty-two of them were
randomized, 21 to the PE-treated group and 21 to the
control group with sham PE treatment (See Fig. 1).
Thirty-nine patients provided baseline and longi-
tudinal data (evaluable population), 19 patients in
the treatment group and 20 patients in the control
group. Twenty-nine patients completed the study
and 13 dropped out: six because AEs (2 anxiety,
2 injuries due to fall, 1 hospitalization due to oti-
tis media, and 1 death), five withdrew consent (by
patient or caregiver), one protocol violation (taking
angiotensin-converting enzyme inhibitor), and one
lost to follow-up.
Baseline demographic, anthropometric, and clini-
cal characteristics of patients are shown in Tables 1
and 2. No significant differences between the charac-
teristics of the two study groups were observed. All
patients received a maximum of 18 PE, with a median
exposure to treatment of 155 days (range: 1–166).
All subjects included in the study and subjected to
at least three PE sessions during the intensive treat-
ment period were considered for efficacy analysis
(ITT population; n = 37) while the PP population was
n = 35. All the 39 evaluable patients were included in
the safety analysis.
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Fig. 1. Flow of patients through the study.
Table 1
Demographic, anthropometric and baseline neuropsychological characteristics of patients in the plasma exchange
(PE)-treated and control (sham PE) groups (mean ± SD or number of subjects and percentage)
All patients PE-treated Control
(N = 39) (N = 19) (N = 20)
Age (years old) 67.7 ± 7.9 68.2 ± 6.7 67.3 ± 9.1
Sex (females) 30 (76.9%) 15 (78.9%) 15 (75.0%)
Height (cm) 159.5 ± 10.3 159.7 ± 11.9 159.4 ± 9.1
Weight (kg) 65.4 ± 15.1 65.4 ± 14.1 65.4 ± 16.3
Duration of symptoms (years) 1.2 ± 0.8 1.0 ± 0.6 1.5 ± 0.9
Global cognitive measures (score)
MMSE 21.5 ± 2.8 22.6 ± 2.7 20.9 ± 3.1
ADAS-Cog 21.7 ± 8.6 18.7 ± 5.9 23.1 ± 10.5
Language/attention tests (score)
BNT 8.4 ± 3.8 8.8 ± 3.7 8.1 ± 3.1
SVF 9.0 ± 3.4 9.8 ± 3.7 8.3 ± 3.1
RAVLT immediate 1 2.7 ± 1.6 2.8 ± 1.5 2.6 ± 1.7
RAVLT immediate 2 3.8 ± 2.0 4.3 ± 2.4 3.4 ± 1.5
RAVLT immediate 3 4.5 ± 2.3 5.2 ± 2.3 3.9 ± 2.1
RAVLT immediate 4 5.0 ± 2.2 5.9 ± 2.1 4.2 ± 2.1
RAVLT immediate 5 5.1 ± 2.4 5.7 ± 2.7 4.6 ± 1.9
RAVLT delayed 0.8 ± 2.0 1.1 ± 2.3 0.6 ± 1.8
SDMT 10.3 ± 9.3 11.2 ± 9.4 9.5 ± 9.3
PVF (F) 5.9 ± 3.6 6.7 ± 3.8 5.1 ± 3.3
PVF (A) 5.0 ± 3.4 5.9 ± 3.3 4.1 ± 3.3
PVF (S) 6.0 ± 4.1 6.5 ± 4.1 5.5 ± 4.2
Behavioral/functional measures (score)
NPI 9.8 ± 9.2 11.5 ± 9.3 8.2 ± 9.1
ADCS-ADL 61.7 ± 7.6 62.4 ± 5.2 61.1 ± 9.5
ADCS-CGIC 3.3 ± 0.6 3.1 ± 0.5 3.5 ± 0.6
CDR-sb 5.2 ± 2.0 4.5 ± 1.7 5.8 ± 2.1
CSDD 3.6 ± 4.4 4.4 ± 4.2 2.8 ± 4.5
No significant differences between the two study groups. ADAS-Cog, Alzheimer’s Disease Assessment Scale – Cognitive
subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study – Activities of Daily Living; ADCS-CGIC, Alzheimer’s
Disease Cooperative Study – Clinical Global Impression of Change; BNT, Boston Naming Test; CDR-sb, Clinical Dementia
Rating - Sum of boxes; CSDD, Cornell Scale for Depression in Dementia; MMSE, Mini-Mental Status Examination; NPI,
Neuropsychiatric Inventory, including: PVF, Phonetic Verbal Fluency; RAVLT, Rey Auditory Verbal Learning Test; SDMT,
Symbol Digit Modalities Test; SVF, Semantic Verbal Fluency.
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Table 2
Clinical characteristics of patients in the plasma exchange-treated
and control groups at study entry
All patients PE-treated Control
(N = 39) (N = 19) (N = 20)
Surgical procedures 33 (84.6%) 18 (94.7%) 15 (75.0%)
Metabolism and
nutrition disorders
26 (66.7%) 7 (36.8%) 19 (95.0%)
Hypercholesterolemia 23 (59.0%) 7 (36.8%) 16 (80.0%)
Psychiatric disorders 26 (66.7%) 12 (63.2%) 14 (70.0%)
Depression 16 (41.0%) 7 (36.8%) 9 (45.0%)
Anxiety 2 (5.13%) 1 (5.3%) 1 (5.0%)
Musculoskeletal and
connective tissue
disorders
16 (41.0%) 9 (47.4%) 7 (35.0%)
Cerebrovascular
disorders
15 (38.5%) 10 (52.6%) 5 (25.0%)
Hypertension 9 (23.1%) 6 (31.6%) 3 (15.0%)
Diabetes 5 (12.8%) 2 (10.5%) 3 (15.0%)
Heart disease 1 (2.6%) 1 (5.3%) 0
Gastrointestinal
disorders
8 (20.5%) 4 (21.1%) 4 (20.0%)
Nervous system
disorders
8 (20.5%) 2 (10.5%) 6 (30.0%)
Administration site
conditions
6 (15.4%) 1 (5.3%) 5 (25.0%)
Renal and urinary
disorders
5 (12.8%) 5 (26.3%) 0
Infections 5 (12.8%) 3 (15.8%) 2 (10.0%)
Renal and urinary
system disorders
5 (12.8%) 5 (26.3%) 0
Immune system
disorders
4 (10.3%) 4 (21.1%) 0
Other disorders
(<10% patients)
17 (43.6%) 9 (47.4%) 8 (40.0%)
No significant differences between the two study groups.
Aβ levels in CSF
Variation of A1–42 levels in CSF between the end
of the last PE and baseline (primary efficacy variable)
showed a higher adjusted (least-squares) mean for
the PE-treated group compared to the control group,
approaching significance (p = 0.072), with values of
75.3 pg/mL (95% CI: –19.8, 170.5) for the PE-treated
group versus –45.5 pg/mL (95% CI: –135.1, 44.2)
for the control group. There were not significant dif-
ferences between the two groups of patients in the
variation of A1–40 levels in CSF between the end
of the last PE and the baseline, with adjusted mean
values of 135.9 pg/mL (95% CI: –954.0, 1225.8) in
the PE-treated group versus 441.5 pg/mL (95% CI:
–585.6, 1468.6) in the control group.
Results of the levels of A1–40 and A1–42
in CSF during the course of the treatment phase
and follow-up are shown in Fig. 2. A1–42 val-
ues of PE-treated patients were consistently higher
than control group (Fig. 2B). At baseline, A1–42
Fig. 2. Levels of A1–40 (A) and A1–42 (B) in cerebrospinal fluid
of plasma exchange (PE)-treated patients and control (sham PE)
during the treatment phase and follow-up periods (Mean ± SD;
N = 14–19; intention-to-treat population). The p value refers
to variation of adjusted (least-squares) mean of A1–42 levels
between the end of the last PE and baseline in the PE-treated group.
mean levels in the PE-treated group and the con-
trols were, respectively, 333.2 ± 151.8 pg/mL and
304.1 ± 121.3 pg/mL; while at the end of last PE the
levels were, respectively, 398.0 ± 273.8 pg/mL and
256.7 ± 100.5 pg/mL. In all the CSF A measure-
ments, results were similar when performed on the
PP population (see Supplementary Tables 1 and 2).
Aβ levels in plasma
Plasma levels of A1–40 and A1–42 measured
before and after each PE showed marked differ-
ences between groups (Fig. 3). In PE-treated patients
the A1–40 levels showed a saw-tooth pattern that
approximately ranged from 100 to 300 pg/mL, while
the A1–42 levels ranged from 20 to 60 pg/mL. The
plasma A1–42 levels were statistically lower after
each treatment period in the PE-treated group com-
pared to the control group (See Fig. 3B). After the
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Fig. 3. Levels of A1–40 (A) and A1–42 (B) in plasma of plasma exchange (PE)-treated patients and controls (sham PE) before and after each
PE, during the three treatment periods (intensive, maintenance I and maintenance II) and follow-up (means without dispersion; N = 18–19;
intention-to-treat population).
treatment periods, plasma A1–40 and A1–42 levels
tended to return to baseline levels during the obser-
vational phase of the study. Results of all plasma A
measurements were similar when performed on the
PP population (available as Supplementary Tables 3
and 4). The relationship between intensity of the treat-
ment and plasma A1–40 mobilization is also shown
as Supplementary Figure 1.
Clinical efﬁcacy outcomes
Table 3 summarizes the changes in the test
scores associated with treatment (treatment effect or
treatment-by-visit effect) after the treatment period
and after the follow-up compared to baseline, in both
patient groups.
PE-treated patients exhibited better scores than
those in the control group in measures of global
cognition (MMSE and ADAS-Cog) during the inter-
vention and observational phases of the study (see
Table 3 and Fig. 4), with a trend to significance
(abstractly considered when p value was from ≥0.05
to <0.12) in favor of the PE-treated group with the
MMSE (mean difference at week 44 : 2.6 [95% CI
–0.8, 6.1]; p = 0.081), and with the ADAS-cog (mean
difference at week 21: –3.6 [95% CI –8.6, 1.5];
p = 0.094).
The PE-treated group had better BNT and SVF
scores throughout the study compared to the con-
trol group, and there was a statistically significant
difference between groups in the treatment-by-visit
effect (see Table 3 and Fig. 5). The mean differences
between PE-treated and control at week 44 were 1.3
(95% CI –1.1, 3.8) for BNT (p = 0.043) and 2.5 (95%
CI 0.1, 5.0) for SVF (p = 0.024).
Similarly, the PE-treated group had better RAVLT1
and RAVLT2 scores than the control group, and there
was a trend to statistical significance favoring the PE-
treated group throughout the study (see Table 3). The
mean differences between PE-treated and control at
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Table 3
Score change from baseline to the end of the treatment and to the end of the follow-up periods in cognition
tests determined in plasma exchange (PE)-treated and control (sham PE) groups. See also Figs. 4, 5, and 6
Test Group scoring bettera Change from baseline (p value)
Treatment-by-visit effect Treatment effect
Global cognition
MMSE PE-treated NS ≥0.05 –<0.12b,c
ADAS-Cog PE-treated NS ≥0.05 –<0.12b,c
Language/attention
BNT PE-treated <0.05b,c NS
SVF PE-treated <0.05c ≥0.05 –<0.12c
RAVLT 1 PE-treated NS ≥0.05 –<0.12c
RAVLT 2 PE-treated NS ≥0.05 –<0.12c
RAVLT 3-5, delayed None NS NS
SDMT None NS NS
PVF (F,A,S) None NS NS
Behavioral/functional
NPI Control <0.05c <0.05b
ADCS-ADL Control NS ≥0.05 –<0.12b,c
ADCS-CGIC Control NS NS
CDR-sb Control NS NS
CSDD None NS NS
aIn the mean score of at least 4/5 or 3/4 of the visits after baseline; bTo week 21 (treatment period); cTo week
44 (follow-up period); NS: non-significant. ADAS-Cog, Alzheimer’s Disease Assessment Scale – Cognitive
subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study – Activities of Daily Living; ADCS-CGIC,
Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change; BNT, Boston Naming Test;
CDR-sb, Clinical Dementia Rating – Sum of boxes; CSDD, Cornell Scale for Depression in Dementia; MMSE,
Mini-Mental Status Examination; NPI, Neuropsychiatric Inventory, including: PVF, Phonetic Verbal Fluency;
RAVLT, Rey Auditory Verbal Learning Test; SDMT, Symbol Digit Modalities Test; SVF, Semantic Verbal
Fluency.
week 44 were 1.5 (95% CI 0.1, 2.9) for RAVLT1
(p = 0.050) and 1.3 (95% CI 0.2, 2.5) for RAVLT2
(p = 0.099).
By contrast, the control group scored better than
the PE-treated group in behavioral (NPI) and func-
tional (ADCS-ADL) measures (see Table 3 and
Fig. 6). The effect was more marked at the end of
the treatment period (week 21), with mean differ-
ences between PE-treated and control of 9.4 (95% CI
–0.2, 18.5) for NPI and –7.1 (95% CI –14.2, 0.1) for
ADCS-ADL. In NPI, statistically significant differ-
ences were observed during both the treatment period
(p = 0.028) and the follow-up (p = 0.048), while in
ADCS-ADL the statistical significance was a trend
(p = 0.050 and p = 0.119, respectively).
Safety results
The rate of AEs was similar between the two treat-
ment groups (see Tables 5 and 6). Out of the 39
evaluable patients, 14 (70.0%) in the control group
underwent at least one adverse event throughout the
study (seven of them moderate to severe) whereas
there were 18 (94.7%) in the PE-treated patients (nine
of them moderate to severe). Five patients (12.8%)
had serious AEs: two of them in the control group:
cholangitis and otitis media; and three patients in
the PE-treated group: hemorrhage associated with the
catheter insertion, complex partial seizures (unrelated
to treatment according to the investigator), and loss
of consciousness (unrelated to treatment according
to the investigator; the patient was admitted to the
ICU and was subsequently diagnosed of a myocardial
infarction, resulting in a multisystem organ failure
and death 2 days later; this patient was submitted to
a PE 2 days prior to the AE).
In the PE-treated group, 18 patients (97.7%) expe-
rienced any AE, seven patients (36.8%) experienced
AEs related to the study intervention, and 15 patients
(78.9%) experienced AEs related to study procedures
(adverse reactions), in contrast to 14 (70.0%), one
(5.0%) and five (25.0%) patients, respectively, in the
control group (p = 0.044, p = 0.014, and p = 0.002,
respectively; Table 4).
The most frequent AE were infections (in 14
patients, mostly device-related); psychiatric disor-
ders (in 14 patients, mostly anxiety); blood and
lymphatic system disorders (in 10 patients, mostly
anemia); nervous system disorders (in six patients,
mostly convulsion/seizure); general and medical
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Fig. 4. Score change from baseline in Mini-Mental Status Examination (MMSE) (A) and Alzheimer’s Disease Assessment Scale – Cognitive
subscale (ADAS-Cog) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean ± 95% CI; N = 18–19;
intention-to-treat population). P-values refer to treatment effect.
device complications (in five patients, mostly
fatigue); and injury and procedural complications
(in five patients, mostly fall). Detailed results for
PE-treated and control group patients are shown in
Table 5.
Five (12.8%) out of the 39 evaluable patients
included in the study reported abnormal laboratory
values. Three of them (7.7%) had low hematocrit and
hemoglobin levels. One patient had high GOT, GPT,
and LDH levels, and one patient had abnormal IgG
levels.
DISCUSSION
This study showed that PE treatment with fresh
therapeutic albumin decreased A1–42 levels in
plasma, and led to borderline increased A1–42 lev-
els in CSF. This effect was associated with a trend to
improvement in patients’ global cognitive measures
(MMSE, ADAS-Cog) during PE treatment and post
PE observational period, as well as with a sustained
improvement in memory and language measures. By
contrast, treated patients had worse scores in behav-
ioral and functional measures during the PE phase,
which improved in the post-PE phase.
The variation in A1–42 levels in CSF between the
end of the last PE and the baseline levels was the pri-
mary efficacy variable. Although the treated group
had higher A1–42 values than the control group
through the course of the treatment phase (Fig. 2),
the difference in the change at baseline versus the
last PE between the two groups of patients was only
close to the level of significance, a trend of increase
that was also observed in the preliminary phase I stud-
ies [22]. This was even with the difference of mean
A1–42 levels at the end of last PE between both
patient groups (around 142 pg/mL) being above the
100 pg/mL that was considered feasible. By contrast,
CSF levels of A1–40 did not change with PE while in
plasma showed a clear saw-tooth pattern associated
with PE periods in the treatment group which was
not present in the control group, as it was also seen
in the preliminary phase I studies [22]. This dissoci-
ation between A1–42 and A1–40 has been found in
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Fig. 5. Score differences with respect to baseline in Boston Naming Test (BNT) (A) and Semantic Verbal Fluency (SVF) (B) tests measured
in plasma exchange (PE)-treated patients and controls (sham PE) (mean ± 95% CI; N = 18–19; intention-to-treat population). P-values refer
to treatment-by-visit effect.
other studies and suggests that A1–40 has a faster
clearance compared to A1–42 [37, 38].
Our findings are consistent with a greater effect of
PE in plasma than in the CSF, which is reasonable
since nearly all cells in the organism generate A
species. While it is thought that the A in CNS orig-
inates in the CNS, the A in plasma is the product
of the APP metabolism in multiple organs, erythro-
cytes, and platelets [39]. Therefore, the A in plasma
partially reflects its metabolism in the CNS. Although
the mechanisms involved in the passage of A from
CSF to plasma are not well understood, there are a
number of receptors that are implicated (e.g., low-
density lipoprotein receptor) [40], and this process
seems to be modulated by APOE [41]. Findings of
this study are in line with our scientific hypothesis:
sequestration of plasma A through PE [39] may alter
the CNS/plasma equilibrium. That is, the decreased
A1–42 in plasma would lead to an accelerated efflux
from CNS to compensate the peripheral drop, and
consequently more A1–42 would be released in the
CNS. Whether the increased CSF A1–42 is a prod-
uct of the normal APP metabolism, the release from
the SNP or both is difficult to determine.
One of the most important, and intriguing, aspects
of this trial is that there was an improvement in
cognitive measures during the PE treatment phase,
which persisted after the treatment was discontinued.
Although bordering statistical significance in some
cases, the results are clinically relevant. The change
from baseline scores in the MMSE and ADAS-Cog
of the PE-treated group were at all time points bet-
ter than those of the control group, as well as most
scores in memory and language functions. A nearly
identical profile was observed in the treated patients
of the preliminary phase I studies [22]. This may
indicate that the removal of A, and perhaps other
unknown proteins, by PE initiates a more durable
process or processes in the CNS that have ben-
eficial effects in cognition. There is an ongoing
clinical study known as the ‘Alzheimer Manage-
ment by Albumin Replacement’ (AMBAR) whose
primary objective is to evaluate cognitive and func-
tional changes in AD patients treated with PE with
albumin and immunoglobulin [42].
Conversely, patients in the control group had bet-
ter behavioral and functional symptoms than those in
the PE group during the treatment phase. However,
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Fig. 6. Score differences with respect to baseline in Neuropsychiatric Inventory (NPI) (A) and Alzheimer’s Disease Cooperative Study –
Activities of Daily Living (ADCS-ADL) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean ± 95%
CI; N = 18–19; intention-to-treat population). P-values refer to treatment-by-visit effect in NPI and to treatment effect in ADCS-ADL.
Table 4
Summary of adverse events in the plasma exchange (PE)-treated
and control (sham PE) groups
PE-treated (N = 19) Control (N = 20)
Any AE 18 (94.7%)∗ 14 (70.0%)
AE related to treatment 7 (36.8%)∗ 1 (5.0%)
Moderate or severe AE 9 (47.0%) 7 (35.0%)
Moderate or severe AE
related to treatment
3 (15.8%) 0
AE related to study
procedures
15 (78.9%)∗∗ 5 (25.0%)
Moderate or severe AE
related to study
procedures
5 (26.3%) 1 (5.0%)
Serious AE 3 (15.8%) 2 (10.0%)
Serious AE related to
study procedures
1 (5.3%) 0
Deceased 1 (5.3%) 0
∗p < 0.05; ∗∗p < 0.01.
the statistical differences subsided during the obser-
vational phase. A possible explanation for this is that
PE has a negative impact on activities of daily liv-
ing during the intensive treatment phases but returns
to baseline levels once the treatment is completed.
Similarly, patients in the control group had better
NPI scores than the PE treated group, although at the
end of the observational phase the treated group had
greater improvement compared to the control group.
This indicates that PE can trigger psychiatric symp-
toms in AD patients, either related to the fact that
the patients had to live with a catheter inserted in the
chest, had discomfort caused by metabolic alterations
related to PE, or both. Indeed, as shown in Table 5,
50% of the patients in the treated group developed
psychiatric symptoms, especially anxiety.
The most frequent AE were infections (28.6%
in controls versus 55.6% in PE-treated patients)
and psychiatric symptoms (35.7% versus 50.0%).
Although there were no statistically significant dif-
ferences between groups in terms of serious AEs, the
incidence of AEs related to the study product or study
procedures was higher in PE-treated patients than in
the controls with sham PE. This is what could be
expected in patients treated with PE [43–45]. PE is
safely used in some neurologic diseases [46] as well
M. Boada et al. / Plasma Exchange and Albumin Replacement in AD 141
Table 5
Adverse events by system organ class, preferred term in the plasma
exchange-treated and control (sham PE) groups
PE-treated (N = 18) Control (N = 14)
Infections 10 (55.6%) 4 (28.6%)
Device-related
infections
5 (27.8%) 1 (7.1%)
Nasopharyngitis 2 (11.1%) 1 (7.1%)
Urinary tract infection 1 (5.6%) 0
Psychiatric symptoms 9 (50.0%) 5 (35.7%)
Aggression 1 (5.6%) 1 (7.1%)
Agitation 0 1 (7.1%)
Anxiety 4 (22.2%) 2 (14.3%)
Depression 1 (5.6%) 0
Blood and lymphatic
system disorders
7 (38.9%) 3 (21.4%)
Anemia 7 (38.9%) 2 (14.3%)
Thrombocytopenia 0 1 (7.1%)
CNS disorders 4 (22.2%) 2 (14.3%)
Grand mal seizures 0 1 (7.1%)
Partial complex seizures 1 (5.3%) 0
Injury and procedural
complications
3 (16.7%) 2 (14.3%)
Fall 2 (11.1%) 2 (14.3%)
General and medical
device complications
3 (16.7%) 2 (14.3%)
Fatigue/asthenia 2 (11.1%) 0
Site hemorrhage 1 (5.6%) 0
Site inflammation 0 1 (7.1%)
Gastrointestinal
disorders
2 (11.1%) 2 (14.3%)
Diarrhea 1 (5.6%) 2 (14.3%)
Deceased 1 (5.6%) 0
as in chronic conditions such as familial hypercholes-
terolemia [47]. In this study, PE showed in general a
comparable safety and tolerability profile. The only
fatal AE (myocardial infarction) was considered not
related to the study product, but could be unlikely
related to the study procedures as a worst-case sce-
nario. It is possible that, in order to optimize the
PE treatment for AD, meaning to achieve maximal
A mobilization with the minimal PE procedures to
reduce AEs, the schedule of the maintenance period
can be reduced.
Possible study limitations would include char-
acteristics of the study product and/or procedures.
Feasibility of albumin replacement treatment previ-
ously studied in vitro showed that Albutein®, the
therapeutic albumin used in this study, was A-free
capable of binding peptides containing the primary
sequence of human A [48] and may also play a
role in oxidation stress associated with AD [49].
However, PE removes albumin, A, and many other
active plasma components. Consequently, the possi-
bility that one or more unidentified agents could play
a role in the observed effects of PE on the AD patients
cannot be ruled out. Indeed, studies conducted in ani-
mal models suggest a role of still-unknown plasma
components in the reversal of age-related cognitive
impairment [50]. On the other hand, the study pop-
ulation was recruited by excluding patients with any
condition that could potentially interfere with PE.
This could be a source of bias. In spite of the relatively
small sample size, this study opens a new avenue for
the treatment of AD, and expands our understanding
of A metabolism.
In conclusion, after PE treatment with 5% human
albumin of AD patients, a measurable modification
in A1–42 concentration in CSF and plasma was
observed, with different patterns of mobilization.
PE treatment was associated with improvement in
memory and language functions compared to control
group patients (sham PE), who showed the cognitive
decline expected in AD.
ACKNOWLEDGMENTS
This study was funded by Grifols. Jordi Bozzo PhD
CMPP (Grifols) is acknowledged for medical writ-
ing and editorial assistance in the preparation of this
manuscript.
Authors’ disclosures available online (http://j-
alz.com/manuscript-disclosures/16-0565r1).
SUPPLEMENTARY MATERIAL
The supplementary material is available in the
electronic version of this article: http://dx.doi.org/
10.3233/JAD-160565.
REFERENCES
[1] Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W,
Breitner JC, Jones B, Lyketsos C, Dulberg C (2004) Inci-
dence and prevalence of dementia in the Cardiovascular
Health Study. J Am Geriatr Soc 52, 195-204.
[2] Becker JT, Boller F, Lopez OL, Saxton J, McGonigle KL
(1994) The natural history of Alzheimer’s disease. Descrip-
tion of study cohort and accuracy of diagnosis. Arch Neurol
51, 585-594.
[3] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ,
Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP,
Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR,
Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012)
National Institute on Aging-Alzheimer’s Association guide-
lines for the neuropathologic assessment of Alzheimer’s
disease. Alzheimers Dement 8, 1-13.
[4] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W,
Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Fer-
ris S, Reichert M, Ketter N, Nejadnik B, Guenzler V,
Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu
142 M. Boada et al. / Plasma Exchange and Albumin Replacement in AD
E, Grundman M, Yuen E, Black R, Brashear HR (2014)
Two phase 3 trials of bapineuzumab in mild-to-moderate
Alzheimer’s disease. N Engl J Med 370, 322-333.
[5] Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B,
Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E,
Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab
for mild-to-moderate Alzheimer’s disease. N Engl J Med
370, 311-321.
[6] Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod
V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W,
Zhang L, Goate A, Benzinger T, Morris JC, Holtzman D,
Bateman RJ (2015) Age and amyloid effects on human cen-
tral nervous system amyloid-beta kinetics. Ann Neurol 78,
439-453.
[7] Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N,
Ihara Y (1994) Visualization of A beta 42(43) and A beta
40 in senile plaques with end-specific A beta monoclonals:
Evidence that an initially deposited species is A beta 42(43).
Neuron 13, 45-53.
[8] Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knop-
man D, Thomas R, Kholodenko D, Schenk D, Lieberburg I,
Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seu-
bert P (1998) High cerebrospinal fluid tau and low amyloid
beta42 levels in the clinical diagnosis of Alzheimer disease
and relation to apolipoprotein E genotype. Arch Neurol 55,
937-945.
[9] Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Mer-
chant C, Small SA, Stern Y, Wisniewski HM, Mehta PD
(1999) Plasma amyloid beta-peptide 1-42 and incipient
Alzheimer’s disease. Ann Neurol 46, 412-416.
[10] Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown
B, Bush AI, De RK, Dromey J, Ellis KA, Faux NG, Foster
J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL,
Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe
CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B,
Ward V, Martins RN, AIBL Research Group (2010) Plasma
amyloid-beta as a biomarker in Alzheimer’s disease: The
AIBL study of aging. J Alzheimers Dis 20, 1233-1242.
[11] Zlokovic BV (2004) Clearing amyloid through the blood-
brain barrier. J Neurochem 89, 807-811.
[12] Shibata M, Yamada S, Kumar SR, Calero M, Bading J,
Frangione B, Holtzman DM, Miller CA, Strickland DK,
Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer’s
amyloid-ss(1-40) peptide from brain by LDL receptor-
related protein-1 at the blood-brain barrier. J Clin Invest
106, 1489-1499.
[13] Marques MA, Kulstad JJ, Savard CE, Green PS, Lee SP,
Craft S, Watson GS, Cook DG (2009) Peripheral amyloid-
beta levels regulate amyloid-beta clearance from the central
nervous system. J Alzheimers Dis 16, 325-329.
[14] Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurd-
son WC, Connors RE, Ovod V, Munsell LY, Mawuenyega
KG, Miller-Thomas MM, Moran CJ, Cross DT III, Derdeyn
CP, Bateman RJ (2014) Amyloid-beta efflux from the
central nervous system into the plasma. Ann Neurol 76,
837-844.
[15] Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak
CS, Fenstermacher JD (1996) Fate of cerebrospinal fluid-
borne amyloid beta-peptide: Rapid clearance into blood and
appreciable accumulation by cerebral arteries. J Neurochem
67, 880-883.
[16] Poduslo JF, Curran GL, Sanyal B, Selkoe DJ (1999)
Receptor-mediated transport of human amyloid beta-
protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol
Dis 6, 190-199.
[17] Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Har-
tikainen P, Soininen H, Pirttila T (2009) Cerebrospinal
fluid beta-amyloid 42 and tau proteins as biomarkers
of Alzheimer-type pathologic changes in the brain. Arch
Neurol 66, 382-389.
[18] DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss
EM, Paul SM, Holtzman DM (2002) Plaque-associated
disruption of CSF and plasma amyloid-beta (Abeta) equilib-
rium in a mouse model of Alzheimer’s disease. JNeurochem
81, 229-236.
[19] Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K,
Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff
K (2003) Novel therapeutic approach for the treatment of
Alzheimer’s disease by peripheral administration of agents
with an affinity to beta-amyloid. J Neurosci 23, 29-33.
[20] Meca-Lallana JE, Rodriguez-Hilario H, Martinez-Vidal S,
Saura-Lujan I, Carreton-Ballester A, Escribano-Soriano JB,
Martin-Fernandez J, Genoves-Aleixandre A, Mateo-Bosch
E, Fernandez-Barreiro A (2003) Plasmapheresis: Its use in
multiple sclerosis and other demyelinating processes of the
central nervous system. An observation study. Rev Neurol
37, 917-926.
[21] Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR,
Chevallier N, Koo EH, Emmerling MR, Roher AE (2000)
Amyloid-beta peptides interact with plasma proteins and
erythrocytes: Implications for their quantitation in plasma.
Biochem Biophys Res Commun 268, 750-756.
[22] Boada M, Ortiz P, Anaya F, Hernandez I, Munoz J, Nunez
L, Olazaran J, Roca I, Cuberas G, Tarraga L, Buendia M, Pla
RP, Ferrer I, Paez A (2009) Amyloid-targeted therapeutics
in Alzheimer’s disease: Use of human albumin in plasma
exchange as a novel approach for Abeta mobilization. Drug
News Perspect 22, 325-339.
[23] McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM (1984) Clinical diagnosis of Alzheimer’s dis-
ease: Report of the NINCDS-ADRDA Work Group under
the auspices of Department of Health and Human Services
Task Force on Alzheimer’s Disease. Neurology 34, 939-944.
[24] Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental
state”. A practical method for grading the cognitive state of
patients for the clinician. J Psychiatr Res 12, 189-198.
[25] Rosen WG, Mohs RC, Davis KL (1984) A new rating scale
for Alzheimer’s disease. Am J Psychiatry 141, 1356-1364.
[26] Smith A (1973) Symbol Digits Modality Test, Western Psy-
chological Services, Los Angeles.
[27] Benton A, Hamsher K (1983) Multilingual aphasia exami-
nation, ASA Associates, Iowa City.
[28] Kaplan E, Goodglass H, Weintraub S (1983) The Boston
naming test, Lea & Febiger, Philadelphia.
[29] Rey A (1964) L’examen clinique en psychologie, Presses
Universitaires de France, Paris.
[30] Cummings JL, Mega M, Gray K, Rosenberg-Thompson
S, Carusi DA, Gornbein J (1994) The Neuropsychiatric
Inventory: Comprehensive assessment of psychopathology
in dementia. Neurology 44, 2308-2314.
[31] Alexopoulos GS, Abrams RC, Young RC, Shamoian CA
(1988) Cornell Scale for Depression in Dementia. Biol Psy-
chiatry 23, 271-284.
[32] Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D
(1986) The Overt Aggression Scale for the objective rating
of verbal and physical aggression. Am J Psychiatry 143,
35-39.
[33] Corrigan JD (1989) Development of a scale for assessment
of agitation following traumatic brain injury. J Clin Exp
Neuropsychol 11, 261-277.
M. Boada et al. / Plasma Exchange and Albumin Replacement in AD 143
[34] Galasko D, Bennett D, Sano M, Ernesto C, Thomas R,
Grundman M, Ferris S (1997) An inventory to assess activi-
ties of daily living for clinical trials in Alzheimer’s disease.
The Alzheimer’s Disease Cooperative Study. Alzheimer Dis
Assoc Disord 11(Suppl 2), S33-S39.
[35] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL
(1982) A new clinical scale for the staging of dementia. Br
J Psychiatry 140, 566-572.
[36] Schneider LS, Olin JT, Doody RS, Clark CM, Morris
JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG,
Ferris SH (1997) Validity and reliability of the Alzheimer’s
Disease Cooperative Study-Clinical Global Impression
of Change. The Alzheimer’s Disease Cooperative Study.
Alzheimer Dis Assoc Disord 11(Suppl 2), S22-S32.
[37] Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman
G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA,
Demattos R (2015) Phase 3 solanezumab trials: Secondary
outcomes in mild Alzheimer’s disease patients. Alzheimers
Dement 12, 110-120.
[38] Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R,
Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC,
Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor
IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M,
Brashear HR (2015) Amyloid-beta 11C-PiB-PET imaging
results from 2 randomized bapineuzumab phase 3 AD trials.
Neurology 85, 692-700.
[39] Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams
P, Svetlik D, Honig LS, Cullum CM, Weiner MF (1997)
Altered amyloid protein processing in platelets of patients
with Alzheimer disease. Arch Neurol 54, 139-144.
[40] Huang Y, Potter R, Sigurdson W, Kasten T, Connors R,
Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M,
Budd SL, Bateman RJ (2012) Beta-amyloid dynamics in
human plasma. Arch Neurol 69, 1591-1597.
[41] Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB,
Patterson BW, Fagan AM, Morris JC, Mawuenyega KG,
Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ,
Holtzman DM (2011) Human apoE isoforms differentially
regulate brain amyloid-beta peptide clearance. Sci Transl
Med 3, 89ra57.
[42] Boada M, Ramos-Ferna´ndez E, Guivernau B, Mun˜oz FJ,
Costa M, Ortiz AM, Jorquera JI, Nunez L, Paez A (2016)
Treatment of Alzheimer’s disease using a combined ther-
apy of plasma exchange and hemopheresis with albumin
and intravenous immunoglobulin: Rationale and therapeu-
tic approach to the AMBAR study (Alzheimer Management
by Albumin Replacement). Neurologı´a 31, 473-481.
[43] Shemin D, Briggs D, Greenan M (2007) Complications of
therapeutic plasma exchange: A prospective study of 1,727
procedures. J Clin Apher 22, 270-276.
[44] Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-
Filipi L, Puretic Z (2005) Complications of therapeutic
plasma exchange: Experience with 4857 treatments. Ther
Apher Dial 9, 391-395.
[45] Mortzell Henriksson M, Newman E, Witt V, Derfler K, Leit-
ner G, Eloot S, Dhondt A, Deeren D, Rock G, Ptak J, Blaha
M, Lanska M, Gasova Z, Hrdlickova R, Ramlow W, Prophet
H, Liumbruno G, Mori E, Griskevicius A, Audzijoniene J,
Vrielink H, Rombout S, Aandahl A, Sikole A, Tomaz J, Lalic
K, Mazic S, Strineholm V, Brink B, Berlin G, Dykes J, Toss
F, Axelsson CG, Stegmayr B, Nilsson T, Norda R, Knut-
son F, Ramsauer B, Wahlstrom A (2016) Adverse events
in apheresis: An update of the WAA registry data. Transfus
Apher Sci 54, 2-15.
[46] Cortese I, Cornblath DR (2013) Therapeutic plasma
exchange in neurology: 2012. J Clin Apher 28, 16-19.
[47] Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg
HN, Masana L, Descamps OS, Wiklund O, Hegele RA,
Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF,
Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna
M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA,
Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR,
Tybjaerg-Hansen A (2013) Familial hypercholesterolaemia
is underdiagnosed and undertreated in the general popu-
lation: Guidance for clinicians to prevent coronary heart
disease: Consensus statement of the European Atheroscle-
rosis Society. Eur Heart J 34, 3478-390a.
[48] Costa M, Ortiz AM, Jorquera JI (2012) Therapeutic albumin
binding to remove amyloid-beta. J Alzheimers Dis 29, 159-
170.
[49] Costa M, Horrillo R, Ortiz AM, Pe´rez A, Herrero P, Canela
N, Boada M, Ruiz A, Herna´ndez I, Afonso N, Torres M,
Grancha S, Jorquera JI (2015) Characterization of albu-
min oxidation status in Alzheimer’s disease patients. J Prev
Alzheimers Dis 2, 370-371.
[50] Villeda SA, Plambeck KE, Middeldorp J, Castellano JM,
Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D,
Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA,
Xie XS, Longo FM, Wyss-Coray T (2014) Young blood
reverses age-related impairments in cognitive function and
synaptic plasticity in mice. Nat Med 20, 659-663.
